Table 1.
Reference Annual Event Riska | Vascular Access Comparison | Meta-Analytical RR (95% CI) | Heterogeneity (I2; P Value) | Number of Additional Events per 1000 Patients Exposed per Year (95% CI) |
---|---|---|---|---|
All-cause mortality | ||||
0.20 for fistula users | Catheter versus fistula | 1.53 (1.40–1.67) | 83.9%; <0.01 | 106 (80–134) excess with catheter |
0.24 for graft users | Catheter versus graft | 1.38 (1.25–1.52) | 86.2%; <0.01 | 91 (60–125) excess with catheter |
0.20 for fistula users | Graft versus fistula | 1.18 (1.09–1.27) | 82.1%; <0.01 | 36 (18–54) excess with graft |
Major cardiovascular events | ||||
0.10 for fistula users | Catheter versus fistula | 1.38 (1.24–1.54) | 0%; 0.47 | 38 (24–54) excess with catheter |
0.11 for graft users | Catheter versus graft | 1.26 (1.11–1.43) | 0%; 0.57 | 28 (12–46) excess with catheter |
0.10 for fistula users | Graft versus fistula | 1.07 (0.95–1.21) | 0%; 0.52 | 7 (−5–21)b excess with graft |
Fatal infections | ||||
0.03 for fistula users | Catheter versus fistula | 2.12 (1.79–2.52) | 0%; 0.82 | 28 (20–38) excess with catheter |
0.04 for graft users | Catheter versus graft | 1.49 (1.15–1.93) | 0%; 0.23 | 17 (5–32) excess with catheter |
0.03 for fistula users | Graft versus fistula | 1.36 (1.17–1.58) | 0%; 0.78 | 9 (4–15) excess with graft |
Outcome measure includes all-cause mortality, fatal or nonfatal cardiovascular events, and fatal infection events as defined in each study, with RRs obtained from the meta-analysis. Reference risks are from the United States Renal Data System.1
The 95% CI includes negative numbers, indicating that the superiority of graft versus fistula for cardiovascular events is uncertain (the 95% CI ranges between 5 fewer events and 21 in excess with grafts).